Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, September 21, 2021
Asymchem announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration.
read more
Tuesday, February 10, 2026
AsymBio, a subsidiary of Asymchem Group , announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, ...
read more
AsymBio has begun construction of a new R&D building at its Shanghai Fengxian site, a move the company said will strengthen its biologics CDMO capabilities and support a full-lifecycle, one-stop service ecosystem.
read more
Astrix, the laboratory digital transformation experts, announced the launch of a dedicated Digital Quality & Compliance practice at the company. This targeted services practice delivers the expertise & guidance to help organizations supercharge their...
read more
Wednesday, February 15, 2023
Global life sciences platform, Gamma Biosciences, which was created by KKR to serve the advanced therapy market with bioprocessing solutions, has agreed to a deal with Biotage AB, a Swedish life sciences company.
read more
Monday, September 20, 2021
Astrea Bioseparations, a leading provider of bioseparations products and services, announced two new investments to enhance operations and customer support resources. The investments include an expansion of the company’s research and development ...
read more
Monday, September 18, 2023
Astrea Bioseparations, a provider of bioseparation and purification technologies announced the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography ...
read more
Bicycle Therapeutics announced it is expanding its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.
read more
AstraZeneca will collaborate with Accent Therapeutics to discover, develop and commercialize therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer.
read more
Friday, November 06, 2015
AstraZeneca has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, California.
read more
Tuesday, October 01, 2019
N-SIDE announced AstraZeneca has signed an agreement to implement the N-SIDE Suite for Clinical Trials.
read more
Tuesday, November 24, 2020
CCT Research announced its partnership with AstraZeneca to advance COVID-19 research. Together with local healthcare providers, CCT will facilitate clinical trials for the AZD1222 COVID-19 VACCINE, an investigational vaccine for the prevention of ...
read more
Monday, November 20, 2023
AstraZeneca has unveiled Evinova, a cutting-edge digital health solutions provider aimed at addressing the diverse needs of healthcare professionals, regulatory bodies, and patients. With steadfast support from AstraZeneca and strategic partnerships ...
read more
Monday, February 29, 2016
AstraZeneca has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for the commercialization rights in China to its calcium channel blocker, Plendil (felodipine).
read more
Wednesday, December 16, 2015
AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced a range of strategic initiatives to accelerate the delivery of innovative biologics and targeted medicines to patients in China, the company’s second ...
read more